Why it matters: Colorectal cancer is the second-leading cause of cancer death, but fewer than 40% of people get screened, because the test itself deters them. A no-sedation, no-prep capsule targets exactly the people who opt out.

What Changed?

PillCam Colon 2 is a capsule roughly the size of a large multivitamin. It contains two cameras, one at each end, that photograph the entire colon as it travels through the gastrointestinal tract. No sedation. No proceduralist. No recovery room. The images transmit wirelessly to a recorder worn around the patient's waist and are reviewed later by a gastroenterologist.


In the Phase 3 trial, 968 patients underwent both PillCam and conventional colonoscopy on the

same day, with endoscopists blinded to PillCam findings. For polyps 6mm or larger, the

clinically meaningful threshold above which removal is recommended, PillCam achieved 88%

sensitivity. For advanced adenomas, the kind most likely to progress to cancer, sensitivity was

87%.


Neither figure matches colonoscopy's near-perfect detection rate. The clinical question is not

whether PillCam is better than colonoscopy. It is whether PillCam in a patient who would

otherwise skip screening entirely is better than no test at all. The answer to that question is

categorical.


The Science

The capsule contains two wide-angle lenses capturing up to 35 frames per second. Its internal

battery lasts eight to 10 hours, long enough to complete colonic transit in most patients.

Unlike the original PillCam SB (designed for the small bowel), PillCam Colon 2 uses an adaptive

frame-rate algorithm that slows image capture in segments where transit is faster, reducing the

chance of missing lesions at bends or in the cecum.


Limitations persist. The capsule cannot biopsy tissue or remove polyps, any positive finding 

still requires a follow-up colonoscopy. Bowel preparation is still required, though a modified, lighter protocol can be used. Approximately 5% of capsules fail to reach the cecum before

battery expiry, requiring a repeat procedure.


The Data

968 patients across seven sites. Sensitivity for polyps ≥6mm: 88%. Sensitivity for advanced

adenoma: 87%. Specificity (avoiding false positives that send people unnecessarily to

colonoscopy): 82%. No serious adverse events attributable to the capsule. 5.4% capsule

retention rate in the cecum, managed with additional laxative administration in most cases.


The trial was powered to demonstrate non-inferiority to colonoscopy within a predefined

margin. PillCam met the primary endpoint for both polyp size thresholds.

Whats Next

The FDA granted PillCam Colon 2 approval for patients who are unable or unwilling to undergo

conventional colonoscopy. The American College of Gastroenterology now includes it in

guidelines as an acceptable alternative for average-risk patients. Medtronic, which acquired

Given Imaging, is running a post-market registry to track real-world detection rates across

diverse bowel preparation compliance profiles.


The relevant question for health systems is not clinical. It is behavioral. If a no-sedation, no-

preparation capsule raises colorectal screening rates by 20 percentage points in populations that

currently opt out, the downstream reduction in late-stage cancer diagnoses would be

substantial. That data will come from registry studies, not trials.